Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

DBCOND0069581Hemic and Lymphatic Diseases Neoplasms

Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: Post-Essential Thrombocythemia Myelofibrosis · Post-Essential Thrombocythemia Related Myelofibrosis · Post Essential Thrombocythemia-myelofibrosis · Post-Essential Thrombocythemia (ET) MF · Post Essential Thrombocythemia Myelofibrosis
Classified under: Hemic and Lymphatic Diseases
Neoplasms
Indicated drugs: Ruxolitinib

Resolves to

Vocabularies

ICD-10D75.81SNOMED CT52967002MedDRA10028537UMLSC0026987

What you can answer from here — as of November 01, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

65Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account